- $568.14m
- $595.14m
- $687.80m
- 69
- 75
- 49
- 70
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 10.55 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.69 | ||
| Price to Tang. Book | 2.18 | ||
| Price to Free Cashflow | 6.85 | ||
| Price to Sales | 0.83 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.09% | ||
| Return on Equity | -37.42% | ||
| Operating Margin | -57.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 714.8 | 744.6 | 684.1 | 673.3 | 687.8 | 673.5 | 696.15 | -0.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -14.75 | +52.36 | -32.16 | -29.66 | n/a | n/a | +12.89 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions. The Company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Company conducts its business in one segment, which provides its medical device products to healthcare providers and patients with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. Its surgical pain and recovery products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. Its interventional pain solutions include COOLIEF chronic pain products, OrthogenRx knee osteoarthritis hyaluronic acid (HA) pain relief injection products (GenVisc and TriVisc) and Trident radiofrequency ablation (RFA) products.
Directors
- Gary Blackford NEC (64)
- Joseph Woody CEO (55)
- Michael Greiner CFO (48)
- Michelle Scharfenberg SVP
- Moji James SVP
- William Haydon SVP (54)
- S. Ross Mansbach SVP
- David Ball SVP (62)
- Arjun Sarker SVP (55)
- John Byrnes IND (62)
- Heidi Kunz IND (67)
- Patrick O'leary IND (63)
- Maria Sainz IND (55)
- Julie Shimer IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 25th, 2014
- Public Since
- October 21st, 2014
- No. of Shareholders
- 8,870
- No. of Employees
- 2,227
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 46,003,150
- Address
- 5405 Windward Parkway, Suite 100 South, ALPHARETTA, 30004
- Web
- https://avanos.com/
- Phone
- +1 6784259273
- Auditors
- Deloitte & Touche LLP
Upcoming Events for AVNS
Q2 2025 Avanos Medical Inc Earnings Release
Similar to AVNS
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avantor
New York Stock Exchange
FAQ
What is the Avanos Medical share price?
As of Today at 19:26 UTC, shares in Avanos Medical are trading at $12.35. This share price information is delayed by 15 minutes.
How has the Avanos Medical share price performed this year?
Shares in Avanos Medical last closed at $12.35 and the price had moved by -30.81% over the past 365 days. In terms of relative price strength the Avanos Medical share price has underperformed the S&P500 Index by -36.14% over the past year.
What are the analyst and broker recommendations for Avanos Medical?
The overall consensus recommendation for Avanos Medical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Avanos Medical dividend yield?
Avanos Medical does not currently pay a dividend.
Does Avanos Medical pay a dividend?
Avanos Medical does not currently pay a dividend.
When does Avanos Medical next pay dividends?
Avanos Medical does not currently pay a dividend.
How do I buy Avanos Medical shares?
To buy shares in Avanos Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avanos Medical?
As of the previous close price of $12.35, shares in Avanos Medical had a market capitalisation of $568.14m.
Where are Avanos Medical shares listed?
Here are the trading details for Avanos Medical:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: AVNS
What kind of share is Avanos Medical?
Based on an overall assessment of its quality, value and momentum Avanos Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avanos Medical share price forecast for 2025?
The analyst consensus target price for shares in Avanos Medical is $17.00. That is 37.65% above the last closing price of $12.35.
Analysts covering Avanos Medical currently have a consensus Earnings Per Share (EPS) forecast of $1.13 for the next financial year.
Find out moreWhat is the trend in the Avanos Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avanos Medical. Over the past six months, its share price has underperformed the S&P500 Index by -41.73%.
As of the last closing price of $12.35, shares in Avanos Medical were trading -34.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avanos Medical PE Ratio?
The Avanos Medical PE ratio based on its reported earnings over the past 12 months is 10.55. The shares last closed at $12.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avanos Medical?
Avanos Medical's management team is headed by:
- Gary Blackford - NEC
- Joseph Woody - CEO
- Michael Greiner - CFO
- Michelle Scharfenberg - SVP
- Moji James - SVP
- William Haydon - SVP
- S. Ross Mansbach - SVP
- David Ball - SVP
- Arjun Sarker - SVP
- John Byrnes - IND
- Heidi Kunz - IND
- Patrick O'leary - IND
- Maria Sainz - IND
- Julie Shimer - IND